You are here

Approvals, Launches, and New Indications

Eisai is first to take advantage of new FDA regulatory pathway
Renflexis also costs 20% less than a biosimilar already on the market
Designed for NICUs, system negates moving babies within the hospital
Patients will be able to avoid hour-long infusions at health care facilities
New single-tablet regiment indicated for genotypes 1 to 6
Adjuvant therapy for HER2-positive tumors indicated after Herceptin treatment
First and only biologic approved that selectively blocks interleukin-23.
Recipients experienced fewer hospital visits for pain and shorter hospital stays
SC formulation can be administered within five to seven minutes
Amphetamine-containing product consists of drug-releasing beads